EMA CHMP provides positive opinion for ViiV’s cabotegravir

2023-07-25
Pharmaceutical Technology
引进/卖出上市批准临床结果临床研究申请上市
EMA CHMP provides positive opinion for ViiV’s cabotegravir
Preview
来源: Pharmaceutical Technology
Cabotegravir LA injectable and tablets are intended for usage as a pre-exposure prophylaxis to cut down HIV-1 infection risk. Credit: PENpics Studio / Shutterstock.com.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided a positive opinion recommending marketing authorisation to ViiV Healthcare’s cabotegravir for human immunodeficiency virus (HIV) prevention.
Cabotegravir long-acting (LA) injectable and tablets are intended for usage as a pre-exposure prophylaxis (PrEP) to cut down HIV-1 infection risk in adults and adolescents.
Recommended Reports
EMA CHMP provides positive opinion for ViiV’s cabotegravir
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rezafungin Acetate in Candidiasis GlobalData
EMA CHMP provides positive opinion for ViiV’s cabotegravir
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - (dolutegravir + GSK3640254) GlobalData
View allCompanies IntelligenceHalozyme Therapeutics IncViiV Healthcare LimitedPREP, INC.C H M P INCFTC Ltd.View all
The latest development is based on findings from two global Phase IIb/III clinical trials which analysed the efficacy and safety of cabotegravir LA for PrEP.
According to the HPTN 083 and HPTN 084 study findings, cabotegravir LA for PrEP demonstrated to be superior to oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) administered daily.
Furthermore, trial subjects who received cabotegravir LA had a 69% and 90% reduced HIV acquisition rate versus FTC/TDF tablets in HPTN 083 and HPTN 084 trials, respectively.
In the US, Zimbabwe, South Africa, Australia, Botswana, Malawi and Brazil, cabotegravir LA for PrEP has received approval under the brand name Apretude.
ViiV Healthcare research and development head Kimberly Smith said: “The expansion of prevention options is critical if we are to end the HIV epidemic.
“Long-acting options have the potential to play an important role in reducing challenges such as inconsistent adherence to taking daily pills, and stigma associated with oral PrEP use that can be faced by people who could benefit from PrEP.”
In June 2021, the company signed a collaboration and licence agreement with Halozyme Therapeutics to develop ‘ultra long-acting’ HIV drugs.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。